Raymond James Financial Services Advisors’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $11.3M | Buy |
22,307
+552
| +3% | +$268K | 0.02% | 811 |
|
|
2024
Q2 | $10.6M | Buy |
21,755
+780
| +4% | +$392K | 0.02% | 799 |
|
|
2024
Q1 | $11.3M | Buy |
20,975
+334
| +2% | +$183K | 0.02% | 750 |
|
|
2023
Q4 | $11.5M | Sell |
20,641
-1,848
| -8% | -$868K | 0.02% | 696 |
|
|
2023
Q3 | $9.83M | Sell |
22,489
-839
| -4% | -$418K | 0.02% | 706 |
|
|
2023
Q2 | $11.7M | Buy |
23,328
+4,548
| +24% | +$2.18M | 0.02% | 649 |
|
|
2023
Q1 | $9.39M | Buy |
18,780
+1,115
| +6% | +$534K | 0.02% | 722 |
|
|
2022
Q4 | $7.21M | Sell |
17,665
-553
| -3% | -$215K | 0.01% | 799 |
|
|
2022
Q3 | $5.93M | Sell |
18,218
-155
| -0.8% | -$56.9K | 0.01% | 842 |
|
|
2022
Q2 | $6.44M | Sell |
18,373
-1,789
| -9% | -$730K | 0.01% | 815 |
|
|
2022
Q1 | $11M | Sell |
20,162
-4,667
| -19% | -$2.45M | 0.02% | 649 |
|
|
2021
Q4 | $16.3M | Sell |
24,829
-1,449
| -6% | -$910K | 0.03% | 504 |
|
|
2021
Q3 | $16.3M | Buy |
26,278
+3,034
| +13% | +$2.04M | 0.03% | 501 |
|
|
2021
Q2 | $14.7M | Buy |
23,244
+102
| +0.4% | +$56.3K | 0.03% | 531 |
|
|
2021
Q1 | $11.3M | Buy |
23,142
+3,198
| +16% | +$1.6M | 0.03% | 573 |
|
|
2020
Q4 | $9.97M | Sell |
19,944
-1,394
| -7% | -$624K | 0.02% | 561 |
|
|
2020
Q3 | $8.39M | Buy |
21,338
+5,830
| +38% | +$2.16M | 0.02% | 567 |
|
|
2020
Q2 | $5.12M | Buy |
15,508
+223
| +1% | +$64.6K | 0.02% | 694 |
|
|
2020
Q1 | $3.7M | Sell |
15,285
-2,716
| -15% | -$709K | 0.02% | 621 |
|
|
2019
Q4 | $4.7M | Buy |
18,001
+1,626
| +10% | +$428K | 0.02% | 750 |
|
|
2019
Q3 | $4.45M | Sell |
16,375
-464
| -3% | -$129K | 0.02% | 741 |
|
|
2019
Q2 | $4.64M | Sell |
16,839
-244
| -1% | -$60.1K | 0.02% | 711 |
|
|
2019
Q1 | $3.82M | Buy |
17,083
+233
| +1% | +$48.1K | 0.02% | 758 |
|
|
2018
Q4 | $3.13M | Buy |
16,850
+976
| +6% | +$200K | 0.02% | 703 |
|
|
2018
Q3 | $3.96M | Buy |
15,874
+1,334
| +9% | +$324K | 0.02% | 740 |
|
|
2018
Q2 | $3.17M | Buy |
14,540
+1,116
| +8% | +$230K | 0.02% | 794 |
|
|
2018
Q1 | $2.57M | Buy |
13,424
+6
| +0% | +$1.11K | 0.01% | 823 |
|
|
2017
Q4 | $2.1M | Buy |
13,418
+3,433
| +34% | +$540K | 0.01% | 903 |
|
|
2017
Q3 | $1.55M | Buy |
9,985
+4,008
| +67% | +$634K | 0.01% | 1039 |
|
|
2017
Q2 | $965K | Sell |
5,977
-47
| -0.8% | -$7.63K | 0.01% | 1301 |
|
|
2017
Q1 | $931K | Buy |
6,024
+1,901
| +46% | +$262K | 0.01% | 1230 |
|
|
2016
Q4 | $484K | Buy |
4,123
+1,720
| +72% | +$196K | ﹤0.01% | 1536 |
|
|
2016
Q3 | $271K | Sell |
2,403
-64
| -3% | -$6.75K | ﹤0.01% | 1853 |
|
|
2016
Q2 | $229K | Buy |
+2,467
| New | +$212K | ﹤0.01% | 1900 |
|
Other funds holding IDXX
Raymond James Financial Services Advisors's IDXX Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its Idexx Laboratories (IDXX) stake by 2.5% in Q3 2024, buying an estimated $268K and bringing the position to 22,307 shares worth $11.3M. The position accounts for 0.02% of the portfolio, ranked #811.
Raymond James Financial Services Advisors first reported a position in IDXX in Q2 2016 and has held it in 34 quarters since. The position peaked at $16.3M in Q4 2021. 1,116 funds tracked by Wall St. Rank hold IDXX as of Q3 2024.
- Raymond James Financial Services Advisors held 22,307 shares of Idexx Laboratories worth $11.3M as of Q3 2024.
- Raymond James Financial Services Advisors bought 552 Idexx Laboratories shares in Q3 2024, an estimated $268K.
- Idexx Laboratories made up 0.02% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #811 holding.
- Raymond James Financial Services Advisors first reported a position in Idexx Laboratories in Q2 2016 and has held it in 34 quarters since.
- Raymond James Financial Services Advisors's Idexx Laboratories position peaked at $16.3M in Q4 2021.
- 1,116 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.